相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity
Oliver Sartor
ONCOLOGIST (2018)
Some statistical considerations in the clinical development of cancer immunotherapies
Bo Huang
PHARMACEUTICAL STATISTICS (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Julia A. Beaver et al.
LANCET ONCOLOGY (2018)
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Alexander N. Shoushtari et al.
JAMA ONCOLOGY (2018)
ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors
Annie Yang et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Targeting Immune Checkpoints in Cancer Therapy
Suzanne L. Topalian
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials
Dickran Kazandjian et al.
SEMINARS IN ONCOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Combination immunotherapy: a road map
Patrick A. Ott et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Lillian L. Siu et al.
CLINICAL CANCER RESEARCH (2017)
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Valsamo Anagnostou et al.
CLINICAL CANCER RESEARCH (2017)
The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members
D. Maillet et al.
ANNALS OF ONCOLOGY (2016)
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
K. M. Morrissey et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Claire F. Friedman et al.
JAMA ONCOLOGY (2016)
Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a common language for the new arena of cancer treatment
Mizuki Nishino
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsaEuro
T. W. Chen et al.
ANNALS OF ONCOLOGY (2015)
Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles
Eve Tang et al.
BMC MEDICINE (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies
Rosemarie Mick et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Adverse Event Reporting in Cancer Clinical Trial Publications
Shanthi Sivendran et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
Julien Peron et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Statistical issues and challenges in immuno-oncology
Tai-Tsang Chen
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
Kenneth F. Schulz et al.
ANNALS OF INTERNAL MEDICINE (2010)
Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction?
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
MENU LABELING: KNOWLEDGE FOR A HEALTHIER AMERICA
Tamara Schulman
HARVARD JOURNAL ON LEGISLATION (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
Better reporting of harms in randomized trials: An extension of the CONSORT statement
JPA Ioannidis et al.
ANNALS OF INTERNAL MEDICINE (2004)
分享论文
